1Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 vl.2, Cancedncidence and Mortality Worldwide: IARC CancerBase No.10 [Intemet]. Lyon, France: International Agency for Research onCancer; 2010. Available from: http://globocan.iarc.fr, 2011-03-12.
2Bookman MA. Trials with impact on clinical management: first line[J]. Int J Gynecol Cancer, 2009, 19(Supp12): $55.
3Ozols R.F, Bundy BN, Greer BE, et al. Phase III trial ofcarboplatin and paclitaxel compared with cisplatin and paclitaxelin patients with optimally resected stage III a gynecologic oncology group study[J]. J ClinOncol, 2003, 21(17): 3194-3200.
4Monk B J, Choi DC, Pugmire G, et al. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelialovarian cancer[J]. Gynecol Oncol, 2005, 96(3): 902-905.
5Curiel TJ, Chang P, Mottram P, et al. Dendritic cell subsets differentially regulate angioganesis in human ovarian cancer[J]. Cancer Res, 2004, 64(16): 5535-5538.
6Kumaran GC, Jayson GC, Clamp AlL Antiangiogenic drugs in ovarian cancer[J]. Br J Cancer, 2009, 100(1): 1-7.
7Byme AT, Ross L, Holash J, et al. Vascular endothelial growth factor- trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model[J]. Clin Cancer Res, 2003, 9(15): 5721-5728.
8Kamba T, Tam BY, l-Iashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature[J]. Am J Physiol Heart Circ Physiol, 2006, 290(2): H560-H576.
9Fukumura D, Jain RK. Tumor microvasculature and targets for anti-angiogenesis and normalization[J] Microvasc Res, 2007, 74(2-3): 72-84.
10Wright JD, Secord AA, Nnnum TM, et al. A multi-institutional evaluation offacors predictive of toxicity and efficacy oibevacizumab for recurrent ovarian cance[J]. Int J Gynecol Cancer, 2008, 18(3): 400-406.
